<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972504</url>
  </required_header>
  <id_info>
    <org_study_id>112864</org_study_id>
    <nct_id>NCT00972504</nct_id>
  </id_info>
  <brief_title>723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess
      the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg)
      and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal
      allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total nasal symptom score 1-7 hours post dose</measure>
    <time_frame>1-7 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>GSK835726 (10mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1004723 (1000mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mcg nasal spray solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetirizine 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg cetirizine as active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK835726 10mg</intervention_name>
    <description>GSK835726 10mg tablet</description>
    <arm_group_label>GSK835726 (10mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1004723 1000mcg</intervention_name>
    <description>GSK1004723 1000mcg nasal spray solution</description>
    <arm_group_label>GSK1004723 (1000mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine 10mg</intervention_name>
    <description>Cetirizine 10mg active comparator</description>
    <arm_group_label>Cetirizine 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match actives</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is healthy apart from seasonal allergic rhinitis, as determined by a
             physician. Can have mild asthma.

          -  Males or female using contraceptives

          -  Aged 18 - 65

          -  Weight 50kg+, BMI 19-32 kg/m2

          -  Exhibit response to Challenge Chamber and skin prick test.

          -  Non-smoker

          -  Capable of giving informed consent

          -  AST and ALT&lt;2xULN; alkaline phosphatase and bilirubin &lt;or=1.5xULN

        Exclusion Criteria:

          -  No nasal structural abnornmality/polyposis, surgery, infection.

          -  any respiratory disease, other than mild asthma or seasonal allergic rhinitis

          -  participated in another clinical study within 30 days.

          -  Subject has donated a unit of blood within 1 month

          -  Use of prescription or non-prescription drugs, including vitamins and st john's wort
             within 7 days of trial.

          -  History of sensitivty to drug

          -  History of alcohol/drug abuse within 12 months.

          -  Positive Hepatitis B antibody test

          -  Positive HIV antibody test

          -  Risk of non-compliance with study protocol

          -  Pregnant or llactating females

          -  Perenial allergic rhinitis

          -  Administration of oral, injectable or dermal corticosteriods within 8 weeks,
             intranasal or inhaled within 3 weeks.

          -  Past or present disease that may affect outcome, as judge by investigator

          -  Specific Immunotherapy within 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84-98. doi: 10.1159/000329738. Review.</citation>
    <PMID>22212854</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 11, 2016</lastchanged_date>
  <firstreceived_date>August 27, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proof of concept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112864</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
